se ha leído el artículo
array:19 [ "pii" => "X0211699500025862" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2000-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2000;20 Supl 1:14-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1599 "formatos" => array:3 [ "EPUB" => 174 "HTML" => 1156 "PDF" => 269 ] ] "itemSiguiente" => array:15 [ "pii" => "X0211699500025854" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2000-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2000;20 Supl 1:16-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2256 "formatos" => array:3 [ "EPUB" => 162 "HTML" => 1700 "PDF" => 394 ] ] "es" => array:8 [ "idiomaDefecto" => true "titulo" => "Papel del TGF- ?1 en la progresión de la Nefropatía Crónica del Injerto renal. Efecto del Bloqueo de la Angiotensina II" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "16" "paginaFinal" => "17" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. M. CAMPISTOL" "autores" => array:1 [ 0 => array:1 [ "nombre" => "J. M. CAMPISTOL" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025854?idApp=UINPBA000064" "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025854/v0_201502091333/es/main.assets" ] "itemAnterior" => array:15 [ "pii" => "X0211699500025870" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2000-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2000;20 Supl 1:13" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2160 "formatos" => array:3 [ "EPUB" => 148 "HTML" => 1629 "PDF" => 383 ] ] "es" => array:8 [ "idiomaDefecto" => true "titulo" => "Efectos del Losartan en los cambios de las uniones intercelulares endoteliales mediados por Angiotensina II" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "13" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "V. ÁLVAREZ CHIVA" "autores" => array:1 [ 0 => array:1 [ "nombre" => "V. ÁLVAREZ CHIVA" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025870?idApp=UINPBA000064" "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025870/v0_201502091333/es/main.assets" ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Angiotensin II and TGF- ? in Progression of Fibrotic Renal Disease: Beyond Hemodynamics" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "14" "paginaFinal" => "15" ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "W. A. BORDER" "autores" => array:1 [ 0 => array:1 [ "nombre" => "W. A. BORDER" ] ] ] ] "textoCompleto" => "NEFROLOGÍA. Vol. XX. Suplemento 1. 2000 «TGF-BETA EN LA PROGRESIÓN DE LA LESIÓN RENAL» Angiotensin II and TGF- in Progression of Fibrotic Renal Disease: Beyond Hemodynamics W. A. Border Fibrosis Research Laboratory. Salt Lake City. Utah. Better understanding of the hemodynamic-independent actions of the renin-angiotensin system (RAS) may lead to improved therapies for renal fibrosis. The conventional view of the RAS is that its role is solely hemodynamic. The RAS maintains systemic blood pressure, modulates glomerular pressure and flow and regulates sodium and potassium transport in the renal tubule. Pharmacologic blockade of the RAS is beneficial in treating hypertension, as well as primary renal and cardiac diseases. The therapeutic benefits are attributed to blocking the hemodynamic effects of RAS e.g., lowering blood pressure or intraglomerular pressure. Of course this is all true, but it appears to be only part of the explanation of the therapeutic effects. Recent findings from several laboratories using different experimental approaches have revealed a whole new dimension to the RAS that is beyond the realm of hemodynamics. This new understanding of the RAS has important clinical implications. It predicts and explains why blockade of the RAS, with angiotensin converting enzyme (ACE) inhibitors, the newer receptor antagonists or both together will significantly slow the progression of renal disease but not stop it i.e., renal protection, but not prevention. However, it further suggests that a combination of angiotensin II blockade with another agent(s) may truly halt progressive fibrosis. The new picture of the biological role of the RAS that is emerging is that it is best viewed as part of a system of interconnected emergency «911» molecules designed to be activated following tissue injury. Correspondence: Wayne A. Border M. D. Fibrosis Research Laboratory 391 Chipeta Way, Suite E Salt Lake City, Utah 84108 The purpose of the «911» molecules is to preserve biological integrity and function by maintaining blood flow, stopping hemorrhage, and initiating the complex task of tissue repair. A paradigm for «911» molecules is the recent discovery that angiotensin II stimulates and enhances the production of both plasminogen activator inhibitor-type I (PAI-I) and transforming growth factor- (TGF-). Why this interconnection? The vital role of the RAS in maintaining blood pressure and organ perfusion in response to volume depletion or blood loss is well understood. PAI-I is key to stabilizing a fibrin clot, that stops hemorrhage and which also acts as a provisional matrix at the initiation of tissue repair. PAI-I also facilitates the deposition of new extracellular matrix by preventing its degradation by newly generated plasmin. TGF-'s role is to deposit new extracellular matrix by simultaneously stimulating its synthesis, inhibiting its degradation by also stimulating PAI-I production and by modulating the expression of new cell matrix receptors that facilitate extracellular matrix deposition. TGF- also regulates the actions of other cytokines that induce cell proliferation and angiogenesis. Thus activation of the RAS leads, not only to protective hemodynamic changes, but also to a comprehensive «911» response to repair injured tissue via induction of PAI-I and TGF-. But herein lies two problems with important clinical implications: 1) If the overexpression of PAI-I and TGF- is not terminated, it will lead to pathological accumulation of extracellular matrix which is fibrosis. 2) Although angiotensin II can activate and sustain a «911» response, blockade of angiotensin II with drugs, even at super doses only partially turns the response off. Thus these drugs slow the progression of fibrosis, but do not stop it. There are several possible reasons for this that are not mutually exclusive. For example, the «911» response may be biologically too important to be easily turned off by blocking only one arm or the 14 ANGIOTENSIN II AND TGF- IN PROGRESSION OF FIBROTIC RENAL DISEASE underlying active disease process may continue to activate the system through pathways other than RAS. This suggests that a combination of angioten- sin II blockade with an agent targeted at other factor(s) might normalize TGF- expression and thus halt progressive renal fibrosis. 15 " "pdfFichero" => "P7-E170-S140-A1868.pdf" "tienePdf" => true ] "idiomaDefecto" => "en" "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025862/v0_201502091333/en/main.assets" "Apartado" => array:4 [ "identificador" => "35407" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Suplementos" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02116995/00000020000000S1/v0_201502091333/X0211699500025862/v0_201502091333/en/P7-E170-S140-A1868.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025862?idApp=UINPBA000064" ]
Idioma original: Inglés
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 5 | 11 | 16 |
2024 Octubre | 37 | 40 | 77 |
2024 Septiembre | 31 | 24 | 55 |
2024 Agosto | 41 | 44 | 85 |
2024 Julio | 32 | 35 | 67 |
2024 Junio | 36 | 21 | 57 |
2024 Mayo | 38 | 31 | 69 |
2024 Abril | 30 | 19 | 49 |
2024 Marzo | 29 | 26 | 55 |
2024 Febrero | 31 | 32 | 63 |
2024 Enero | 19 | 18 | 37 |
2023 Diciembre | 15 | 19 | 34 |
2023 Noviembre | 24 | 32 | 56 |
2023 Octubre | 28 | 30 | 58 |
2023 Septiembre | 19 | 22 | 41 |
2023 Agosto | 18 | 24 | 42 |
2023 Julio | 21 | 26 | 47 |
2023 Junio | 27 | 16 | 43 |
2023 Mayo | 28 | 22 | 50 |
2023 Abril | 20 | 15 | 35 |
2023 Marzo | 14 | 19 | 33 |
2023 Febrero | 16 | 17 | 33 |
2023 Enero | 27 | 20 | 47 |
2022 Diciembre | 27 | 17 | 44 |
2022 Noviembre | 23 | 29 | 52 |
2022 Octubre | 31 | 44 | 75 |
2022 Septiembre | 33 | 24 | 57 |
2022 Agosto | 29 | 30 | 59 |
2022 Julio | 34 | 41 | 75 |
2022 Junio | 21 | 27 | 48 |
2022 Mayo | 18 | 26 | 44 |
2022 Abril | 29 | 38 | 67 |
2022 Marzo | 28 | 40 | 68 |
2022 Febrero | 30 | 36 | 66 |
2022 Enero | 23 | 20 | 43 |
2021 Diciembre | 24 | 40 | 64 |
2021 Noviembre | 22 | 24 | 46 |
2021 Octubre | 21 | 46 | 67 |
2021 Septiembre | 21 | 22 | 43 |
2021 Agosto | 23 | 33 | 56 |
2021 Julio | 15 | 27 | 42 |
2021 Junio | 14 | 22 | 36 |
2021 Mayo | 19 | 27 | 46 |
2021 Abril | 17 | 47 | 64 |
2021 Marzo | 25 | 16 | 41 |
2021 Febrero | 22 | 8 | 30 |
2021 Enero | 10 | 14 | 24 |
2020 Diciembre | 14 | 7 | 21 |
2020 Noviembre | 11 | 11 | 22 |
2020 Octubre | 15 | 4 | 19 |
2020 Septiembre | 11 | 4 | 15 |
2020 Agosto | 14 | 8 | 22 |
2020 Julio | 11 | 7 | 18 |
2020 Junio | 10 | 8 | 18 |
2020 Mayo | 13 | 6 | 19 |
2020 Abril | 17 | 10 | 27 |
2020 Marzo | 8 | 9 | 17 |
2020 Febrero | 24 | 14 | 38 |
2020 Enero | 30 | 13 | 43 |
2019 Diciembre | 10 | 13 | 23 |
2019 Noviembre | 3 | 4 | 7 |
2019 Octubre | 4 | 5 | 9 |
2019 Septiembre | 12 | 15 | 27 |
2019 Agosto | 8 | 8 | 16 |
2019 Julio | 10 | 10 | 20 |
2019 Junio | 5 | 5 | 10 |
2019 Mayo | 7 | 20 | 27 |
2019 Abril | 35 | 22 | 57 |
2019 Marzo | 9 | 6 | 15 |
2019 Febrero | 7 | 11 | 18 |
2019 Enero | 9 | 5 | 14 |
2018 Diciembre | 17 | 17 | 34 |
2018 Noviembre | 19 | 7 | 26 |
2018 Octubre | 16 | 8 | 24 |
2018 Septiembre | 20 | 6 | 26 |
2018 Agosto | 20 | 7 | 27 |
2018 Julio | 14 | 5 | 19 |
2018 Junio | 10 | 4 | 14 |
2018 Mayo | 15 | 13 | 28 |
2018 Abril | 16 | 2 | 18 |
2018 Marzo | 10 | 2 | 12 |
2018 Febrero | 14 | 5 | 19 |
2018 Enero | 8 | 4 | 12 |
2017 Diciembre | 11 | 5 | 16 |
2017 Noviembre | 13 | 5 | 18 |
2017 Octubre | 15 | 2 | 17 |
2017 Septiembre | 12 | 3 | 15 |
2017 Agosto | 18 | 7 | 25 |
2017 Julio | 13 | 2 | 15 |
2017 Junio | 15 | 5 | 20 |
2017 Mayo | 9 | 0 | 9 |
2017 Abril | 11 | 1 | 12 |
2017 Marzo | 14 | 1 | 15 |
2017 Febrero | 8 | 2 | 10 |
2017 Enero | 4 | 0 | 4 |
2016 Diciembre | 17 | 2 | 19 |
2016 Noviembre | 22 | 3 | 25 |
2016 Octubre | 40 | 5 | 45 |
2016 Septiembre | 29 | 2 | 31 |
2016 Agosto | 50 | 1 | 51 |
2016 Julio | 51 | 0 | 51 |
2016 Junio | 65 | 0 | 65 |
2016 Mayo | 74 | 0 | 74 |
2016 Abril | 26 | 0 | 26 |
2016 Marzo | 30 | 0 | 30 |
2016 Febrero | 31 | 0 | 31 |
2016 Enero | 31 | 0 | 31 |
2015 Diciembre | 49 | 0 | 49 |
2015 Noviembre | 37 | 0 | 37 |
2015 Octubre | 28 | 0 | 28 |
2015 Septiembre | 29 | 0 | 29 |
2015 Agosto | 21 | 0 | 21 |
2015 Julio | 20 | 0 | 20 |
2015 Junio | 8 | 0 | 8 |
2015 Mayo | 14 | 0 | 14 |